US panel gives mixed vote to Protein Sciences' cell-based flu vaccine FluBlok
This article was originally published in Scrip
Executive Summary
Protein Sciences' novel trivalent seasonal influenza vaccine FluBlok (purified recombinant influenza haemagglutinin) is effective in subjects up to age of 49 years but not in older populations, and data do not support the cell-based vaccine's safety in all adults, the US FDA's experts have said.